At the news
? BULLISHIMPACT 6/10 8-K filed May 4, 2026 at 08:00 ET
Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in PSC, meeting the primary endpoint with high statistical significance (p<0.0001) and a robust placebo-adjusted improvement in pruritus. The company plans a pre-NDA meeting with the FDA in summer 2026 and an NDA submission in H2 2026, positioning volixibat as a potential first treatment for cholestatic pruritus in PSC.
- Primary endpoint met in VISTAS Phase 2b study of volixibat in PSC (p<0.0001).
- Placebo-adjusted improvement of 1.64 points on Adult ItchRO scale.
- 55.6% of volixibat patients achieved 2-point reduction vs 26.3% for placebo (p=0.0019).
- Pre-NDA meeting with FDA scheduled for summer 2026; NDA submission planned H2 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access